The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Genetics in Medicine

• Publication date

  2011-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/GIM.0b013e3182174703PMID 21637107PMCID PMC3954622
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.

  2010cited by this paper
• A randomized study of alglucosidase alfa in late-onset Pompe's disease.

  2010cited by this paper
• Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.

  2010cited by this paper
• Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?

  2009cited by this paper
• How we treat a hemophilia A patient with a factor VIII inhibitor.

  2009cited by this paper
• Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease

  2009cited by this paper
• Elimination of antibodies to recombinant enzyme in Pompe's disease.

  2009cited by this paper
• Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease

  2009cited by this paper
• Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

  2008cited by this paper
• Advances in hemophilia: experimental aspects and therapy.

  2008cited by this paper
• Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.

  2008cited by this paper
• Deconstructing Pompe Disease by Analyzing Single Muscle Fibers: “To See a World in a Grain of Sand…”

  2007cited by this paper
• Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease

  2007cited by this paper
• Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.

  2007cited by this paper
• Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

  2007cited by this paper
• Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.

  2007cited by this paper
• A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.

  2006cited by this paper
• Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.

  2006cited by this paper
• Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.

  2005cited by this paper
• Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry.

  2003cited by this paper
• The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.

  2003cited by this paper
• Induction of Tolerance to a Recombinant Human Enzyme, Acid Alpha-Glucosidase, in Enzyme Deficient Knockout Mice

  2003cited by this paper
• Antibodies against rHuEPO: native and recombinant.

  2002cited by this paper
• Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders

  2002cited by this paper
• Enzyme-replacement therapy in mucopolysaccharidosis I.

  2001cited by this paper
• Human immune response to recombinant human proteins.

  2001cited by this paper
• Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.

  2001cited by this paper
• Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats.

  2000cited by this paper
• Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease.

  2000cited by this paper
• Enzyme Replacement Therapy in Mucopolysaccharidosis I: Altered Distribution and Targeting of α-l-Iduronidase in Immunized Rats

  2000cited by this paper
• Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

  1998cited by this paper
• Motor Assessment of the Developing Infant

  1994cited by this paper
• Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase

  1993cited by this paper
• Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase.

  1993cited by this paper
• Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children.

  1991cited by this paper
• Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children

  1991cited by this paper
• Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin.

  1988cited by this paper
• Pre- and postnatal pathology, enzyme treatment, and unresolved issues in five lysosomal disorders.

  1978cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Early Initiation of Enzyme Replacement Therapy in Infantile Onset Pompe Disease Improves Cardiac Outcomes: A Longitudinal Analysis

  2026cites this paper
• A comprehensive study on the effect of alglucosidase alpha and immunomodulation on survival, motor and cardiac outcome, creatine kinase and antibody titers in classic infantile Pompe disease: the Monza experience.

  2026cites this paper
• Insights into immunogenicity and therapeutic strategies to mitigate the immune response in infantile-onset Pompe disease: a comprehensive systematic literature review

  2026cites this paper
• Assessment of Immune Responses Against AAV Encoded Transgene Products

  2026cites this paper
• Infantile-onset Pompe disease entering adulthood: insights from two decades of enzyme replacement therapy experience.

  2025cites this paper
• Phosphatidylserine exposure on tolerogenic nanoparticle correlate with oral tolerance

  2025cites this paper
• Diagnosis, management and monitoring of patients with Pompe disease in the UK

  2025cites this paper
• A Real-World Data Analysis of Alglucosidase Alfa in the FDA Adverse Event Reporting System (FAERS) Database

  2025cites this paper
• The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa.

  2025cites this paper
• Ten-Year Follow-Up of Taliglucerase Alfa in Type 1 Gaucher Disease: Real-World Evidence from Albania

  2025cites this paper
• Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease

  2025cites this paper
• Prenatal Delivery of Enzyme Replacement Therapy to Fetuses Affected by Early‐Onset Lysosomal Storage Diseases

  2025cites this paper
• Determination of the Epitopes of Alpha-Glucosidase Anti-Drug Antibodies in Pompe Disease Patient Plasma Samples

  2025cites this paper
• Desensitization of olipudase alfa-induced anaphylaxis in a child with chronic neurovisceral acid sphingomyelinase deficiency

  2024cites this paper
• Optimizing clinical outcomes: The journey of twins with CRIM-negative infantile-onset Pompe disease on high-dose enzyme replacement therapy and immunomodulation

  2024cites this paper
• Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease.

  2024cites this paper
• Advances in Immune Tolerance Induction in Enzyme Replacement Therapy

  2024cites this paper
• Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy

  2024cites this paper
• Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease

  2024cites this paper
• Dose-intensive therapy (DIT) for infantile Pompe disease: A pilot study

  2024cites this paper
• Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

  2024cites this paper
• An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation

  2024cites this paper
• Restoring immune balance with Tregitopes: A new approach to treating immunological disorders.

  2024cites this paper
• Opportunities for nanomaterials in enzyme therapy.

  2024cites this paper
• Polymer-Based Drug Delivery Systems Under Investigation For Enzyme Replacement And Other Therapies Of Lysosomal Storage Disorders.

  2023cites this paper
• Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions

  2023cites this paper
• Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice

  2023cites this paper
• Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease.

  2023cites this paper
• Screening data from 19 patients with late‐onset Pompe disease for a phase I clinical trial of AAV8 vector‐mediated gene therapy

  2023cites this paper
• Therapeutics in paediatric genetic diseases: current and future landscape

  2023cites this paper
• Phase I Study of Liver Depot Gene Therapy in Late-onset Pompe Disease.

  2023cites this paper
• Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives

  2023cites this paper
• Long-Term Outcome of Infantile Onset Pompe Disease Patients Treated with Enzyme Replacement Therapy - Data from a German-Austrian Cohort

  2023cites this paper
• Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review

  2023cites this paper
• Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification

  2023cites this paper
• Glycogen storage diseases

  2023cites this paper
• Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease

  2023cites this paper
• Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement

  2023cites this paper
• Outside the fiber: Endomysial stromal and capillary pathology in skeletal muscle may impede infusion therapy in infantile-onset Pompe disease.

  2023cites this paper
• Gene therapy for glycogen storage diseases

  2023cites this paper
• The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review

  2023cites this paper
• Non-specificity of symptoms in infantile-onset Pompe disease may delay the diagnosis and institution of treatment

  2022cites this paper
• Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease

  2022cites this paper
• Isogenic GAA-KO Murine Muscle Cell Lines Mimicking Severe Pompe Mutations as Preclinical Models for the Screening of Potential Gene Therapy Strategies

  2022cites this paper
• Genetic variants of Pompe disease among a sample of Egyptian pediatric patients

  2022cites this paper
• Enzyme-responsive polymersomes ameliorate autophagic failure in a cellular model of GM1 gangliosidosis

  2022cites this paper
• Infantile‐onset Pompe disease with neutropenia: Treatment decisions in the face of a unique phenotype

  2022cites this paper
• Minimum Effective Dose to Achieve Biochemical Correction with Adeno-Associated Virus Vector-Mediated Gene Therapy in Mice with Pompe Disease

  2022cites this paper
• Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies.

  2022cites this paper
• Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease

  2022cites this paper
• Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders

  2022cites this paper
• Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs

  2022cites this paper
• Long-term outcomes of very early treated infantile-onset Pompe disease with short-term steroid premedication: experiences from a nationwide newborn screening programme

  2022cites this paper
• IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy

  2022cites this paper
• A Multi-Centre Prospective Study of the Efficacy and Safety of Alglucosidase Alfa in Chinese Patients With Infantile-Onset Pompe Disease

  2022cites this paper
• A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation

  2022cites this paper
• Infantile-onset Pompe disease complicated by sickle cell anemia: Case report and management considerations

  2022cites this paper
• Modifying enzyme replacement therapy – A perspective

  2022cites this paper
• Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel

  2022influential citation
• Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease

  2022cites this paper
• What’s new and what’s next for gene therapy in Pompe disease?

  2022influential citation
• Reacciones de hipersensibilidad a alglucosidasa alfa en enfermedad de Pompe: dos casos de desensibilización exitosa

  2022cites this paper
• Clinical Development of Cell Therapies to Halt Lysosomal Storage Diseases: Results and Lessons Learned.

  2021cites this paper
• Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease

  2021cites this paper
• Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via Newborn Screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction

  2021cites this paper
• Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins

  2021cites this paper
• Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

  2021cites this paper
• Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses.

  2021cites this paper
• Immune response with long-term memory triggered by amorphous aggregates of misfolded anti-EGFR VHH-7D12 is directed against the native VHH-7D12 as well as the framework of the analogous VHH-9G8.

  2021cites this paper
• Identification and Affinity Determination of Protein-Antibody and Protein-Aptamer Epitopes by Biosensor-Mass Spectrometry Combination

  2021cites this paper
• Pharmacological Chaperone Therapy for Pompe Disease

  2021cites this paper
• Therapeutic Approaches in Lysosomal Storage Diseases

  2021cites this paper
• Heiminfusionstherapie bei Morbus Pompe: Konsensusempfehlungen für den deutschsprachigen Raum

  2021influential citation
• Preclinical studies for plant-based oral enzyme replacement therapy (Oral-ERT) in Pompe disease knockout mice with transgenic tobacco seeds expressing human GAA (tobrhGAA)

  2021cites this paper
• Anti-Taliglucerase Alpha Antibodies Associated with Lower Efficacy of ERT and Onset of Autoimmune Thyroiditis in a Patient with Type 1 Gaucher Disease

  2020cites this paper
• Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease.

  2020cites this paper
• The Challenge of Gene Therapy for Neurological Diseases: Strategies and Tools to Achieve Efficient Delivery to the Central Nervous System

  2020cites this paper
• Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort

  2020cites this paper
• Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease

  2020cites this paper
• A Race Against Time—Changing the Natural History of CRIM Negative Infantile Pompe Disease

  2020cites this paper
• Pompe disease: genetics and management

  2020influential citation
• Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies

  2020cites this paper
• Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients

  2020influential citation
• Clinical and Molecular Features of Our Pompe Patients: Single-Center Experience

  2020cites this paper
• Targeted delivery of acid alpha-glucosidase corrects skeletal muscle phenotypes in Pompe disease mice

  2020cites this paper
• Pediatric Pulmonology

  2020influential citation
• Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres

  2020cites this paper
• Newborn Screening for Pompe Disease

  2020cites this paper
• Diagnosis and Care of Infants and Children with Pompe Disease

  2020cites this paper
• Management of Hypersensitivity Reactions to Enzyme Replacement Therapy in Children with Lysosomal Storage Diseases.

  2020cites this paper
• Pulmonary outcome measures in long‐term survivors of infantile Pompe disease on enzyme replacement therapy: A case series

  2020cites this paper
• Pharmacological Therapy in Inborn Errors of Metabolism

  2020cites this paper
• Airway abnormalities in very early treated infantile‐onset Pompe disease: A large‐scale survey by flexible bronchoscopy

  2020cites this paper
• Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease

  2019cites this paper
• Progress and challenges of gene therapy for Pompe disease.

  2019cites this paper
• Challenges in treating Pompe disease: an industry perspective.

  2019influential citation
• Long-term outcome and unmet needs in infantile-onset Pompe disease.

  2019cites this paper
• Improving diagnosis and treatment outcomes in mucopolysaccharidoses

  2019cites this paper
• Effects of immunomodulation in classic infantile Pompe patients with high antibody titers

  2019cites this paper
• Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease.

  2019cites this paper